Drug Profile


Alternative Names: Ciflox; CIPRO; Ciprobay; Ciprofloxacin hydrochloride; Ciproxan; Ciproxin; Ciproxine; Cunesin

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer
  • Class Antibacterials; Cyclopropanes; Fluoroquinolones; Piperazines; Small molecules
  • Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute sinusitis; Anthrax; Gonorrhoea; Intestinal infections; Intra-abdominal infections; Nosocomial pneumonia; Respiratory tract infections; Skin and soft tissue infections; Typhoid; Urinary tract infections

Most Recent Events

  • 26 Jul 2016 The US FDA approved label for ciprofloxacin carries a boxed warning
  • 15 Mar 2016 Biomarkers information updated
  • 02 Nov 2012 Bayer and Medsintez agree to manufacture and market anti-infective ciprofloxacin in Russia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top